Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
Senba
Hiroaki
H
Kawano
Mikihiko
M
Kawakami
Masanobu
M
D001629:Bezafibrate / Q000009:adverse effects*; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone; D001629:Bezafibrate